TOKYO & BASKING RIDGE, N.J., July 17, 2025--ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2+ Metastatic Breast Cancer ...

ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

A stage-four cancer diagnosis once sounded like the end of the road – after all, there is no stage five. When Joe Biden’s prostate cancer was recently labelled “aggressive” and described ...

AstraZeneca's quarterly revenue beat expectations, boosted by its oncology and biopharmaceuticals segments and strong U.S. demand. The Anglo-Swedish pharmaceutical giant said Tuesday that for the ...

Trastuzumab deruxtecan-nxki (Enhertu; AstraZeneca, Daiichi Sankyo), commonly known as T-DXd, demonstrated the most efficacy in patients with HER2-positive disease, who had a real-world PFS of 1 year.

Home Investing Wellness Stocks to Invest in Now Breakthroughs that help us live longer, healthier lives can also create opportunities for investors.

AstraZeneca today announces $50 billion of investment in the United States by 2030, building on America’s global leadership in medicines manufacturing and R& ...

Shares in the AI darling were trending in pre-market trading after finishing Monday’s session almost 2% higher as retail investors remain bullish on the stock. The renewed optimism can be traced to ...